Individual Congress Registration Form

To be returned by fax or e-mail with a copy of the bank transfer to: Arseducandi – Viale Gian Galeazzo 3 – 20136 Milan, Italy - Fax +39 0258189386 – thrombosis2010@arseducandi.it

One copy of this form should be completed for each participant. Please type or print clearly in BLOCK CAPITALS, and provide the information as you wish it to appear on your name badge.

Personal Information Mr. Mrs. Ms. Prof. MD.

Last name (family name) _____ First Name (given name) _____

Date of birth _____

Hospital/Institution _____ Department _____

P.O. Box/Street Address _____

City _____ State _____

Post Code/Zip _____ Country _____

Fiscal Code for Italian delegates _____ VAT number _____

Fax _____ Phone _____ E-mail _____

MLTD membership number _____ Passport N. _____

Please choose the appropriate registration fee

☐ **Registration fees: MLTD members**
Early – before 28 February: € 540.00 + VAT 20% = € 648.00
Regular – after 28 February: € 630.00 + VAT 20% = € 756.00
Late – after 30 June: € 675.00 + VAT 20% = € 810.00

☐ **Registration fees: non-members**
Early – before 28 February € 600,00 + VAT 20% = € 720,00
Regular – after 28 February € 700,00 + VAT 20% =€ 840,00
Late – after 30 June € 750,00 + VAT 20% =€ 900,00

☐ **Registration fees: students** (copy of student ID required)
€ 250.00 + VAT 20% = € 300.00

The opening ceremony and welcome evening to be held on 6 July is covered by the delegates' registration fee:

☐ I will attend the opening ceremony

☐ I will not attend the opening ceremony

Payment
I have transferred the total amount to Banca Nazionale del Lavoro - Ag. 2 – Milan
IBAN: IT10R01005 01602 000000015392 – SWIFT BIC: BNLIITRR – BENEFICIARY: Arseducandi Srl
Reference: **Participant name – 21st International Congress on Thrombosis 2010**
Bank transfers are not allowed after 25 June 2010.
You will receive an invoice as confirmation of your registration by e-mail.
Please contact Arseducandi if you require any further information on congress registration.

Your personal data will be processed pursuant to the provisions of Italian law 196/03 on the protection of privacy.

Place, Date Signature

…….…… ……..……

Please note: we do not accept personal cheques, company cheques or eurocheques.
Admission to the congress is granted only if Arseducandi has received the registration fee. Delegates who have made late payments must bring proof of payment to the congress.

Please tick the topics you are interested in:

Tuesday 6-07-2010

- ☐ 14.30-16.30 ***SATELLITE SYMPOSIUM: Thrombotic microangiopathies (Baxter)***
  The genetic basis of congenital thrombotic thrombocytopenic purpura (TTP). **(Flora Peyvandi)**
  New therapies in acquired TTP. **(Marie Scully)**
  New diagnostic and prognostic aspects of acquired TTP**. (Johanna Kremer-Hovinga)**
  Rethinking thrombotic microangiopathies. **(Giuseppe Remuzzi)**

- ☐ 14.30-16.30 ***SATELLITE SYMPOSIUM: New perspectives in thrombosis research (ETRO)***
  Complete deficiency of ADAMTS13 is suffcient to cause TTP in non-human primates. **(H.B. Feys, N. Vandeputte, J. Roodt, S. Lamprecht, W.J. Van Rensburg, V.J. Louw, P.N. Badenhorst, H. Deckmyn, K. Vanhoorelbeke)**
  Aspirin resistance: myth or reality? **(L. Muszbek, Z. Bereczky, E. Kovács, É. Katona, L. Balogh, N. Hormoródi, I. Édes)**
  Environment and lifestyle: can they affect the response to antiplatelet agents? **(G. De Gaetano)**
  Arterial thrombosis in antiphospholipid syndrome. **(J. Musial, J. Swadzba, A. Matyja-Bednarczyk, T. Iwaniec)**

- ☐ **16.30-18.30** ***OPENING SYMPOSIUM: Air pollution and thrombosis***
  Air pollution, blood clotting, and cardiovascular disease: evidence from epidemiological studies and impact on the population. **(Annette Peters)**
  Beyond the DNA sequence: epigenetic mechanisms of prothrombotic air pollution effects. **(Andrea Baccarelli)**
  Inhaled particles and thrombosis: a toxicology perspective from air pollution to nanoparticles. **(Nicholas L. Mills)**

- ☐ 18:30-19:00 PLENARY LECTURE: Discovery of drugs in haemostasis and thrombosis by serendipity. **(Meyer Michel Samama)**
- ☐ 19:30-20:00 PLENARY LECTURE: Looking for novel therapeutic targets: the role of clinical research. **(A. Maseri)**

Wednesday 7-07-2010

- ☐ 8:00-8:30 Haemotransfusion in coronary heart disease: friend or foe? **(Maddalena Lettino)**
- ☐ 8:00-8:30 Hypercoagulability and thrombosis in sickle cell anemia and thalassemia**. (David Varon)**
- ☐ 8:00-8:30 Leukocytosis as a thrombosis risk factor**. (Tiziano Barbui)**
- ☐ 8:30-9:00 New antiplatelet agents: why they are badly needed by the cardiologist. **(Piera Angelica Merlini)**
- ☐ 8:30-9:00 Familial thrombophilia without a positive laboratory screening. **(Jacqueline Conard)**
- ☐ 8:30-9:00 Metabolic modulation of inflammation-driven coagulation**. (Erik Stroes)**
- ☐ 11:30-12:30 DEBATE: Is it clinically useful to extend to the calf the ultrasound examination of deep leg veins? SM Schellong (Yes) vs Gualtiero Palareti (No)
- ☐ 11:30-12:00 LECTURE: Role of Statins and exercise on vulnerable plaques. **(Christos Liapis)**
- ☐ 12:00-12:30 LECTURE: Thrombosis in neonates and children. **(U. Nowack-Göttl)**

- **13:00-14:30** ***SATELLITE SYMPOSIUM: Current trends in the management and prevention of venous thromboembolic disease (Bayer Healthcare)***
  The epidemiology of venous thromboembolism and experience with its management in Italy. **(W. Ageno)**
  The burden of venous thromboembolism in the hospital setting. **(A. Cohen)**
  What can ongoing clinical trials of anticoagulants demonstrate? **(H. Büller)**
  Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement: the RECORD study program. **(L. Borris)**

- **13:00-14:30** ***SYMPOSIUM: Advances in thrombosis. Joint symposium of Grupo Cooperativo Latinoamericano de Hemostasia Y Trombosis (CLAHT) & Mediterranean League Against Thromboembolic Diseases (MLTD)***
  Antiphospholipid syndrome. **(R. Forastiero)**
  Thrombotic complications in the treatment of patients with bleeding disorders. **(M. Mijares)**
  The European Action on Anticoagulation: randomized study of computer-assisted oral anticoagulant dosage versus medical staff dosage. **(L. Poller)**
  Thrombosis prophylaxis in the ambulatory cancer patient: approaches to identify the high risk patient. **(K. Bauer)**

- **15.00-16.30** ***SATELLITE SYMPOSIUM: Thrombosis and antithrombotic therapy: what have we learnt in the low-molecular-heparin era? (SANOFI AVENTIS)***
  How are biosimilar LMWHs currently used and what is the expected future? **(Ajay J Kakkar)**
  Recommendations for preparation of biosimilar LMWHs according the SSC on Anticoagulation of the ISTH compared to FDA and EMEA views. **(Job Harenberg)**
  Biostatistical requirements for development of biosimilar LMWHs **(Patrick Mismetti)**

- **15.00-16.30** ***SATELLITE SYMPOSIUM: Heparin Induced Thrombocytopenia (HIT) diagnosis and treatment (Instrumentation Lab)***
  HIT: Pathophysiology, Incidence and Guidelines. **(Andreas Greinacher)**
  Laboratory aspects in HIT diagnosis: Current Status. **(Ismail Elalamy)**
  Clinical Aspects and Challenges in Patient Management. **(Gualtiero Palareti)**

- **15.00-16.30** ***SATELLITE SYMPOSIUM: Xa inhibition in the whole spectrum of venous thromboembolism: new insights (Glaxo Smith Kline)***
  Superficial vein thrombosis (SVT): recent epidemiology data. **(A. Leizorovicz)**
  Pharmacological treatment of SVT: what is the evidence. **(H. Decousus)**
  Pharmacological management of deep vein thrombosis and pulmonary embolism. **(H. Büller)**
  SVT management guidelines. **(K. Bauer)**

- **17.00-18.00** **SYMPOSIUM: Venous Thromboembolism in special clinical conditions: natural history.**
  VTE and estrogen therapy (oral contraceptive and hormone-replacement). (Benjamin Brenner)
  VTE in the very elderly. (Alan Leizorovicz)
  VTE in the very young. (Manuel Monreal)

- **17.00-18.00** **SYMPOSIUM: Advances in peripheral arterial disease.**
  Peripheral arterial disease in the spectrum of atherothrombosis. (Gordon D.O. Lowe)
  Asymptomatic peripheral arterial disease: impact in clinical practice. (Francesco Violi)
  Antiplatelet treatment. (Gregory Y. Lip)

- **17.00-18.00** **SYMPOSIUM: Genomewide association studies.**
  Stroke. (Monique Breteler)
  Venous thromboembolism. (Pierre Morange)
  Coronary artery disease. (Sekar Kathiresan)

Thursday 8-07-2010

- 8:00-8:30 Biomarkers for the diagnosis of venous thromboembolism. **(Arnaud Perrier)**
- 8:00-8:30 Moderate hyperhomocysteinemia: marker or cause of a disease? **(R. Abbate)**
- 8:00-8:30 Antiplatelet therapy in diabetics. **(Sergio Cocchieri)**
- 8:30-9:00 Cerebral vein thrombosis. **(Jose Ferro)**
- 8:30-9:00 Which antithrombotic and antiplatelet therapies in the ambulance for acute coronary syndrome? **(M.Tubaro)**
- 8:30-9:00 Pharmacoepidemiology of gastrointestinal bleeding complications of antiplatelet agents. **(A. Lanas)**

- 11:30-12:30 DEBATE: Variable antiplatelet response to thyenopiridines: should we use lab tests?
  J. Collet (Yes) vs B. Rocca (No)
- 11:30-12:00 LECTURE: Adjunctive antithrombotic agents to amplify thrombolysis in ischemic stroke. **(J. Grotta)**
- 12:00-12:30 LECTURE:Discovery of quantitative trait loci involved in platelet function. **(William Ouwehand)**

- **13.00-14.30** ***SATELLITE SYMPOSIUM: Transforming the management of venous and arterial thrombosis (Boehringer Ingelheim)***
  Venous and arterial thromboembolism: the causes and consequences. **(W. Ageno)**
  Primary prevention of VTE after hip or knee arthroplasty: experience with dabigatran etexilate. **(B. Eriksson)**
  New developments in the treatment of acute VTE. **(P. Mismetti)**
  Stroke prevention in atrial fibrillation: changing the paradigm? **(R. de Caterina)**

- **15.00-16.00 Focus on thrombin receptor antagonists as antiplatelet agents (Schering Plough)**
  Limitations of currently available antiplatelet drugs. **(C. Patrono)**
  Thrombin receptor antagonist as a novel approach for the treatment of atherothrombosis. **(G. Ambrosio)**

- **16:00-16:30** ***Satellite Lecture*** *Optimizing antiplatlet therapy: insight from large outcome trials.*
  (Diego Ardissino)(Astra Zeneca)

- **15.00-16.30 Advancing the field of anticoagulation: oral factor Xa inhibitors (Bristol Myers Squibb and Pfizer)**
  Pharmacology of the new oral anticoagulants. **(J. Eikelboom)**
  Recent trials of oral factor Xa inhibitors in orthopaedic surgery. **(M.R. Lassen)**
  Future perspectives in oral anticoagulation. **(R. de Caterina)**

- **15.00-16.30 The use of low molecular weight heparins (LMWH) in special clinical settings (Rovi)**
  Extension of thromboprophylaxis after surgery for cancer. **(P.Prandoni)**
  Management of LMWHs in renal impairment and elderly patients. **(S. Rico)**
  Prevention of venous thromboembolism (VTE) during pregnancy. **(A. Santamaria)**

- **17.00-18.30 SYMPOSIUM: New anticoagulants: highlights on methodological issues.**
  Lack of standard between antithrombotic trials in orthopedics; The scenario. (O.E. Dahl)
  Methodological issues in trials assessing primary prophylaxis of venous thromboembolism. (Marc Samama)
  Make Clinical studies in medical patients closer to usual hospital care. (Job Harenberg)
  Guidelines on clinical testing of new antithrombotics in surgical populations. (Ajay K.Kakkar)

- **17.00-18.30 SYMPOSIUM: Therapeutic advances in stroke.**
  Thrombolysis in acute stroke: present evidences and future perspectives. (Danilo Toni)
  Secondary prevention of cerebral ischemia of arterial origin. (Ale Algra)
  Secondary prevention of cardioembolic stroke: old and new drugs. (J Ferro)

- **17.00-18.30 SYMPOSIUM: Platelets and inflammation.**
  Platelets and atherosclerosis. (Meinrad Gawaz)
  Platelets and allergic disorders. (Paolo Gresele)
  Platelets, inflammation and acute coronary syndrome. (Lina Badimon)

Friday 9-07-2010

- 8:00-8:30 Thromboprophylaxis in "minor" orthopedic surgery**. (Henri Bounameaux)**
- 8:00-8:30 Antithrombotic agents after vascular surgery. **(David Bergqvist)**
- 8:00-8:30 A renaissance of the contact phase of blood coagulation. **(Uri Seligsohn)**
- 8:30-9:00 News on the anticoagulant pathway of blood coagulation. **(Javier Corral)**
- 8:30-9:00 Highlights of the International Conference on Thrombosis and Hemostasis Issues in Cancer (ICTHIC) 2010. **(Anna Falanga)**
- 8:30-9:00 What is new on the clinical aspects of fibrinolysis and thrombolysis. **(Jose A Paramo)**

- 11:30-12:30 DEBATE: Thromboembolic Pulmonary Hypertension: Watchful waiting vs. early surgery. Piovella vs D'Armini
- 11:30-12:00 LECTURE: The future of anticoagulant therapy. **(G. Agnelli)**
- 12:00-12:30 LECTURE: The role of tissue factor in coronary artery disease. **(T.F. Luscher)**

- **13.00-14.30 SYMPOSIUM: Venous and arterial thromboembolism: an overlapping risk.**
  Clinical VTE and subsequent risk of arterial thrombotic events in non-provoked populations. **(Gordon D.O. Lowe)**
  Surgical triggering of venous and arterial thromboembolism: Immediate and long-term consequences. **(Ola E. Dahl)**
  Pregnancy and obstetric complications and the link to venous and arterial thrombosis. **(Ian Greer)**

- **13.00-14.30 SYMPOSIUM: Special problems and strategies in anticoagulation.**
  Bridging strategies for interruption of anticoagulation for invasive procedures**.** **(Sam Schulman)**
  Antisense anticoagulant treatment. **(Marcel Levi)**
  Anticoagulant and thrombolytic treatment of portal vein and digestive tract thrombosis. **(Frank Leebeek)**

- **13.00-14.30 SYMPOSIUM: Atrial fibrillation and heart failure as thrombotic disorders.**
  Atrial fibrillation as a thrombotic disease. **(G. Y Lip)**
  Heart failure and thrombotic complications. **(C. Torp-Pedersen)**
  Heart failure as a hypercoaguable state. **(PW Kamphuisen)**

- **15.00-16.30 SYMPOSIUM: The benefits and risks of low-dose aspirin in primary prevention of atherothrombosis.**
  Should aspirin be used for the primary prevention of vascular disease? **(Colin Baigent)**
  Aspirin for people with diabetes: current evidence and ongoing trials. **(Jane Armitage)**
  Ongoing trials on aspirin for primary prevention: will they deliver? **(Gianni Tognoni)**

- **15.00-16.30 SYMPOSIUM: Long-term complications of venous thromboembolism.**
  The optimal duration of anticoagulant therapy in patients with venous thromboembolism **(Paolo Prandoni)**
  The post-thrombotic syndrome: prevalence, prognostication and need for progress. **(Susan Kahn)**
  Chronic thromboembolic pulmonary hypertension. **(Irene Lang)**

- **15.00-16.30 SYMPOSIUM: Dietary habits and cardiovascular risk.**
  Is the evidence from observational studies sufficient to state that Mediterranean Diet reduces CV risk? **(A. Kafatos)**
  Alcohol and cardiovascular risk: is there a window for benefits? **(A. Di Castelnuovo)**
  Food and health: is inflammation the round-about? **(M.I. Covas)**

☐ I have read and accepted the Terms and Conditions

Arseducandi Srl, with registered office at Viale Gian Galeazzo 3, Milan (MI), the Holder and Processor of the client's personal data, hereby informs you that said data is processed in electronic or hard copy by its employees, and possibly by parent companies that have received appropriate mandates and instructions to prevent the loss, destruction, unauthorised access or processing thereof, as well as by companies contracted to carry out administrative services. Personal data will not be distributed, but communicated to parties* to whom this is necessary for the execution of their contractual duties or when legally required.

Personal data is gathered and used for the purposes of:

1. managing the registration procedure on the websites: www.thrombosis2010.pvagency.it - www.thrombosis2010.arseducandi.it

2. sending material and communications on initiatives promoted by Promoviaggi Spa and Arseducandi Srl, as well as on the advantages and offers reserved for registered users on the site;

3. understanding clients' interests based on their choices and preferences, and using this knowledge to send registered users, by post, e-mail, text message or MMS, offers relating to science education programmes only;

4. sending personal data to the Mediterranean League in order to check clients are registered as members.

For the purposes of points 2, 3 and 4, the client must consent or deny permission by checking the appropriate box below.

The provision of personal data is optional, but certain items (marked with an asterisk) are required for clients to register on the site and make purchases.

The client is vested with the rights pursuant to article 7 of Legislative Decree 196/2003, and therefore has the right to: obtain confirmation as to the existence of personal data concerning him/her in the Data Holder's records and its communication; know the source of the data, and the logic, purposes and methods of its processing; obtain updating, correction, addition, erasure, anonymisation or blocking of data that has been unlawfully processed; object to its use.

To enforce their rights set out in article 7 of said decree, clients may apply to the Data Holder Company or its manager responsible for processing personal data. They may request an updated list of persons responsible for processing personal data by e-mailing info@arseducandi.it, heading the e-mail "Re: Legislative Decree 196/2003". Letters sent by post should be addressed to: Arseducandi Srl – Viale Gian Galeazzo, 3 - 20136 Milan (MI), with the envelope marked: "Re: Legislative Decree 196/2003". For requests by telephone, please call +39 02 58189242.

* an updated list of names is available from the Marketing department of the Data Holder, tel: +39 02 58189242.

☐ I have read the information and consent to the processing of my personal data for the profiling purposes set out under point 4, even in the event that the undersigned is not yet registered with the Mediterranean League. I further agree to receive specific mailings and newsletters.